Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pectasol-C Modified Citrus Pectin Targets Galectin-3-Induced Stat3 Activation and Synergize Paclitaxel Cytotoxic Effect on Ovarian Cancer Spheroids Publisher Pubmed



Hossein G1 ; Halvaei S1 ; Heidarian Y1, 2 ; Dehghanighobadi Z1 ; Hassani M1 ; Hosseini H1 ; Naderi N3 ; Sheikh Hassani S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Animal Biology, Developmental Biology Laboratory, College of Science, University of Tehran, Tehran, Iran
  2. 2. Department of Cell and Molecular Biology, Kish International Campus, University of Tehran, Kish, Iran
  3. 3. Neuroscience Research Center, Shahid Beheshti University (Medical Sciences), Tehran, Iran
  4. 4. Department of Gynecology Oncology Valiasr, Imam Khomeini Hospital, Tehran University of Medical Science, Tehran, Iran

Source: Cancer Medicine Published:2019


Abstract

Here we sought to determine the relationship between STAT3 activity and Galectin-3 (Gal-3) and to investigate the cytotoxic effect of PectaSol-C Modified Citrus Pectin (Pect-MCP) as a specific competitive inhibitor of Galectin-3 (Gal-3) in combination with Paclitaxel (PTX) to kill the ovarian cancer cell SKOV-3 multicellular tumor spheroid (MCTS). To this order, SKOV-3 cells in 2D and 3D cultures were treated with exogenous Gal-3 for the assessment of STAT3 activity. Two-way ANOVA main effect and IC50 of each drug Paclitaxel (PTX) and Pect-MCP or in combination were obtained from MTT assay results. The phosphorylated STAT3 levels, migration, invasion, integrin mRNA and p-AKTser473 levels were assessed in the absence or presence of each drug alone or in combination. Gal-3 expression levels were assessed in human serous ovarian cancer (SOC) specimens and its correlation with different integrin mRNA levels was further assessed. Our results showed that Gal-3 expression level was significantly increased in MCTS compared to monolayer SKOV-3 cells which triggered STAT3 phosphorylation. Moreover, Pect-MCP synergized with PTX to kill SKOV3 MCTS through abrogation of STAT3 activity and reduced expression of its downstream target HIF-1α, reduced integrin mRNA levels, and subsequently decreased AKT activity. There were higher expression levels of Gal-3 in human high-grade SOC specimens compared to the normal ovary and borderline SOC which positively and significantly correlated with α5, β2 and β6 integrin mRNA levels. Together, these results revealed for the first time that Pect-MCP could be considered as a potential drug to enhance the PTX effect on ovarian cancer cells MCTS through inhibition of STAT3 activity. © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Related Docs
1. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
2. Dacomitinib, a Pan-Inhibitor of Erbb Receptors, Suppresses Growth and Invasive Capacity of Chemoresistant Ovarian Carcinoma Cells, Scientific Reports (2017)
3. Blockade of Vascular Endothelial Growth Factor Receptors by Tivozanib Has Potential Anti-Tumour Effects on Human Glioblastoma Cells, Scientific Reports (2017)
4. Egfr Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells, Iranian Biomedical Journal (2020)
5. Blockade of Nuclear Factor-Κb (Nf-Κb) Pathway Inhibits Growth and Induces Apoptosis in Chemoresistant Ovarian Carcinoma Cells, International Journal of Biochemistry and Cell Biology (2018)
6. Anti-Tumour Activity of Tivozanib, a Pan-Inhibitor of Vegf Receptors, in Therapy-Resistant Ovarian Carcinoma Cells, Scientific Reports (2017)
Experts (# of related papers)
View all Related Experts
Seyed Hamidollah Ghaffari (5)
Ahmad Reza Dehpour (4)